Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: Effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant

Journal of Medical Microbiology

Volumn 44, Issue 6, 1996, Pages 425-433

  Sjostrom J E ^a   Larsson, H ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ERYTHROMYCIN; METRONIDAZOLE; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CELL PH; DRUG POTENTIATION; GROWTH REGULATION; HELICOBACTER PYLORI; NONHUMAN; PRIORITY JOURNAL;

EID: 0029972904     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-44-6-425     Document Type: Article

References (40)

1. Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991; 6: 105-113.
2. Graham DY, Malaty HM, Evans DG, Evans DJ, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100: 1495-1501.
3. Marshall BJ, Barrett JL, Prakash C, McCallum RW, Guerrant RE. Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 1990; 99: 697-702.
4. Goodwin CS, Collin MD, Blincow E. The absence of thermoplasmaquinones in Campylobacter pyloridis, and its temperature and pH growth range. Microbios Letters 1986; 32: 137-140.
5. Goodwin CS, Armstrong JA. Microbiological aspects of Helicobacter pylori (Campylobacter pylori). Eur J Clin Microbiol Infect Dis 1990; 9: 1-13.
6. Morgan DR, Freedman R, Depew CE, Kraft WG. Growth of Campylobacter pylori in liquid media. J Clin Microbiol 1987; 25: 2123-2125.
7. Kangatharalingam N, Amy PS. Helicobacter pylori comb. nov. exhibits facultative acidophilism and obligate microaerophilism. Appl Environ Microbiol 1994; 60: 2176-2179.
8. Greig MA, Neithercut WD, Hossack M, McColl KEL. Harnessing of urease activity of Helicobacter pylori to induce self-destruction of the bacterium. J Clin Pathol 1991; 44: 157-159.
9. Eaton KA, Brooks CL, Morgan DR, Krakowka S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 1991; 59: 2470-2475.
10. Ferrero RL, Lee A. The importance of urease in acid protection for the gastric-colonising bacteria, Helicobacter pylori and Helicobacter felis sp. nov. Microb Ecol Health Dis 1991; 4: 121-134.
11. Mobley HL, Hausinger RP. Microbial ureases: significance, regulation, and molecular characterization. Microbiol Rev 1989; 53: 85-108.
12. Engel E, Peskoff A, Kauffman GL, Grossman MI. Analysis of hydrogen ion concentration in the gastric gel mucus layer. Am J Physiol 1984; 247: G321-338.
13. 3 transport: characteristics and proposed role in acidity regulation and mucosal protection. Am J Physiol 1982; 242:; G183-193.
14. Glupczynski Y. In vitro susceptibility testing of Helicobacter pylori to antimicrobial agents: basis for treatment of microbiologists' obsession? Zentralbl Bakteriol 1993; 280: 227-238.
15. Glupczynski Y, Burette A, Labbe M, Deprez C, De Reuck M, Deltenre M. Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol 1988; 83: 365-372.
16. Hirschl AM., Hentschel E, Schütze K et al. The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer. Scand J Gastroenterol 1988; 23 Suppl 142: 76-81.
17. Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GNJ. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40.
18. Chiba N, Rademaker JW, Rao BV, Hunt RH. Eradication of Helicobacter pylori-meta-analysis to determine optimal therapy. Gut 1991; 32: A1220-A1221.
19. Tytgat GNJ, Axon ATR, Dixon MF, Graham DY, Lee A, Marshall BJ. World Congresses of Gastroenterology. Working Party Reports 36-45. Melbourne, Australia, Blackwell Scientific Publications.
20. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter prylori with triple therapy. Gastroenterology 1992; 102: 493-496.
21. Pavicic MJ, Namavar F, Verboom T, van Winkelhoff AJ, De Graaff J. In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations. Antimicrob Agents Chemother 1993; 37: 1184-1186.
22. van Caekenberghe DL, Breyssens J. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother 1987; 31: 1429-1430.
23. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-889.
24. Malanoski GJ, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 1993; 12: 131-133.
25. McNulty CAM. Bacteriological and pharmacological basis for the treatment of Campylobacter pylori infection. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Oxford, Blackwell Scientific Publications. 1989: 209-216.
26. Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol 1989; 24 Suppl 167: 49-54.
27. Bazzoli F, Zagari RM, Fossi P et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-777.
28. Lind T, Veldhuyzen van Zanten SJO, Unge P et al. The MACH 1 study: optimal one-week treatment for H. pylori defined? Gut 1995; 37 Suppl 1: A4.
29. Millar MR, Pike J. Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori. Antimicrob Agents Chemother 1992; 36: 185-187.
30. Mégraud F, Trimoulet P, Lamouliatte H, Boyanova L. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells. Antimicrob Agents Chemother 1991; 35: 869-872.
31. Ferrero RL, Cussac V, Courcoux P, Labigne A. Construction of isogenic urease-negative mutants of Helicobacter pylori by allelic exchange. J Bacteriol 1992; 174: 4212-4217.
32. Miles AA, Misra SS, Irwin JO. The estimation of the bactericidal power of the blood. J Hyg 1938; 38: 732-748.
33. Krogstad DJ, Moellering RC. Antimicrobial combinations. In: Lorian V (ed) Antibiotics in laboratory medicine. 2nd edn. Baltimore, The Williams and Wilkins Co. 1986: 537-595.
34. Dick JD. A new twist to an old disease. Anna Rev Microbiol 1990; 44: 249-269.
35. Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986; 39: 353-365.
36. Neithercut WD, Greig MA, Hossack M, McColl KEL. Suicidal destruction of Helicobacter pylori: metabolic consequence of intracellular accumulation of ammonia. J Clin Pathol 1991; 44: 380-384.
37. Coudron PE, Kirby DF. Comparison of rapid urease test, staining techniques, and growth on different solid media for detection of Campylobacter pylori. J Clin Microbiol 1989; 27: 1527-1530.
38. Shahamat M, Mai UEH, Paszko-Kolva C, Yamamoto H, Colwell RR. Evalution of liquid media for growth of Helicobacter pylori. J Clin Microbiol 1991; 29: 2835-2837.
39. Barry AL, Jones RN, Thornsberry C. In vitro activities of Azithromycin (CP 62,993), Clarithromycin (A-56268; TE-031), Erythromycin, Roxithromycin, and Clindamycin. Antimicrob Agents Chemother 1988; 32: 752-754.
40. Logan RPH, Gummett PA, Hegarty BT, Walker MM, Baron JH, Misiewicz JJ. Clarithromycin and omeprazole for Helicobacter pylori. Lancet 1992; 340: 239.